Document Detail

Role of the cholinesterase inhibitors in the treatment of schizophrenia.
MedLine Citation:
PMID:  23330829     Owner:  NLM     Status:  Publisher    
The effects of cognitive impairment on the occupational functioning, social activity, and economic life of patients with schizophrenia constitute major obstacles to recovery. Currently, the standard biological treatment for schizophrenia consists of antipsychotic medications, which results in significant improvements in psychotic symptoms such as delusions and hallucinations via a high affinity for numerous neurotransmitter receptors. However, the effects of antipsychotics on cognitive dysfunction appear very limited or minimal in clinical practice. In fact, according to recent clinical trials, newer antipsychotics, which have little effect on cholinergic receptors but potent antagonistic effects on the serotonin-7 receptor (5-HT(7); e.g., lurasidone), may ameliorate cognitive defects in patients with schizophrenia. It has been consistently reported that both nicotinic and muscarinic receptors play crucial roles in cognition and, thus, that they may be considered potential therapeutic targets for new drugs designed to decrease cognitive deficits. Accordingly, cholinesterase inhibitors (ChEIs) may be effective in enhancing the cognitive functioning of patients with schizophrenia. Not surprisingly, such drugs have been utilized to treat cognitive deficits in patients with schizophrenia in a handful of clinical trials. This paper reviews a brief background information and discusses current clinical issues regarding the use of ChEIs in patients with schizophrenia.
Chi-Un Pae
Related Documents :
23140769 - Symptomatological and cognitive correlates of vascular comorbidity in older-elderly (at...
23567399 - The peaceful mind program: a pilot test of a cognitive-behavioral therapy-based interve...
25129819 - Malnutrition among cognitively intact, noncritically ill older adults in the emergency ...
23176609 - Schizophrenia patients with and without post-traumatic stress disorder (ptsd) have diff...
24940959 - Effect of hormone replacement therapy on cognitive function in women with chronic schiz...
2236379 - Estimating psychiatric morbidity by logistic regression: application to post-natal depr...
25109109 - Evaluation of the quality of life in adolescents with acne.
21063639 - Difference in asthma control test™ (act) scores in three different clinical practice ...
23083699 - How do psychological variables influence coping strategies in inflammatory bowel disease?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-21
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  -     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
The Catholic University of Korea College of Medicine, Bucheon St. Mary's Hospital, Department of Psychiatry , 2 Sosa-Dong, Wonmi-Gu, Pucheon, Kyounggi-Do 420-717 , Republic of Korea ;
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diffusing Colloidal Probes of Protein-Carbohydrate Interactions.
Next Document:  Racial Disparities in Left Main Stenting: Insights from a Real World Inner City Population.